{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:47:23Z","timestamp":1770410843426,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3898,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1093\/annonc\/mdn692","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T03:33:41Z","timestamp":1232076821000},"page":"709-714","source":"Crossref","is-referenced-by-count":77,"title":["Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"B.","family":"Esmaeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Banay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wayne Saville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn692_bb0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood-2006-02-005017","article-title":"Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options","volume":"108","author":"Decaudin","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn692_bb0015","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdn692_bb0020","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0046-8177(90)90181-4","article-title":"Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987","volume":"21","author":"Knowles","year":"1990","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdn692_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0161-6420(98)92107-8","article-title":"Malignant tumors of the orbit: analysis of the Florida Cancer Registry","volume":"105","author":"Margo","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mdn692_bb0030","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/djj248","article-title":"Rapidly increasing incidence of ocular non-Hodgkin lymphoma","volume":"98","author":"Moslehi","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdn692_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1442-9071.2001.d01-18.x","article-title":"Ocular adnexal lymphoproliferative disease: a series of 73 cases","volume":"29","author":"McKelvie","year":"2001","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1093\/annonc\/mdn692_bb0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ohc.2004.11.001","article-title":"Ocular adnexal lymphoma: classification, clinical disease, and molecular biology","volume":"18","author":"Bardenstein","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1093\/annonc\/mdn692_bb0045","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0161-6420(98)98024-1","article-title":"Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases","volume":"105","author":"Coupland","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mdn692_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-8140(00)00328-5","article-title":"Orbital lymphoma: radiotherapy outcome and complications","volume":"59","author":"Stafford","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0161-6420(01)00547-4","article-title":"Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma","volume":"108","author":"Shields","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mdn692_bb0060","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0360-3016(03)00767-3","article-title":"Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes","volume":"57","author":"Fung","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1093\/annonc\/mdn692_bb0065","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/archopht.125.12.1663","article-title":"Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma","volume":"125","author":"Hatef","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1093\/annonc\/mdn692_bb0070","first-page":"809","article-title":"Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy","volume":"110","author":"Gayed","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1093\/annonc\/mdn692_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0360-3016(98)00535-5","article-title":"Radiotherapy in the management of orbital lymphoma","volume":"44","author":"Bolek","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdn692_bb0080","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0360-3016(02)02966-8","article-title":"Curative radiotherapy for primary orbital lymphoma","volume":"54","author":"Bhatia","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdn692_bb0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/annonc\/mdm457","article-title":"Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma","volume":"19","author":"Song","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0090","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","article-title":"Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit","volume":"113","author":"Ben Simon","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mdn692_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1389201013378563","article-title":"Monoclonal antibodies: a new era in the treatment of non-Hodgkin\u2019s lymphoma","volume":"2","author":"Grillo-Lopez","year":"2001","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1093\/annonc\/mdn692_bb0100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"66","author":"Cvetkovic","year":"2006","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdn692_bb0105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdn692_bb0110","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn692_bb0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MOH.0b013e32818a6daf","article-title":"Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma","volume":"14","author":"Winter","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdn692_bb0120","first-page":"10","article-title":"Radioimmunotherapy for non-Hodgkin\u2019s lymphomas: a historical perspective","volume":"30","author":"Press","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0125","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1080\/10428190600923140","article-title":"Current results and future applications of radioimmunotherapy management of non-Hodgkin\u2019s lymphoma","volume":"47","author":"Santos","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdn692_bb0130","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/biot.200700043","article-title":"Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma?","volume":"2","author":"Chapuy","year":"2007","journal-title":"Biotechnol J"},{"key":"10.1093\/annonc\/mdn692_bb0135","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0140","first-page":"1225","article-title":"Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1093\/annonc\/mdn692_bb0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0150","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn692_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium-90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdn692_bb0160","first-page":"595","article-title":"Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin\u2019s lymphoma (NHL) (abstract)","volume":"22","author":"Emmanouilides","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10.1093\/annonc\/mdn692_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/09553008214550451","article-title":"Radiosensitivity of human B-lymphocytic lymphomas in vitro","volume":"41","author":"Johansson","year":"1982","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"10.1093\/annonc\/mdn692_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.IOP.0000115594.98470.AC","article-title":"Monoclonal antibody treatment of orbital lymphoma","volume":"20","author":"Sullivan","year":"2004","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1093\/annonc\/mdn692_bb0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.leukres.2004.05.011","article-title":"Rituximab in primary conjunctival lymphoma","volume":"29","author":"Zinzani","year":"2005","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdn692_bb0180","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdn692_bb0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-007-0301-y","article-title":"Rituximab and chlorambucil as first line treatment for low-grade ocular adnexal lymphomas","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdn692_bb0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0360-3016(94)90348-4","article-title":"Severe dry-eye syndrome following external beam irradiation","volume":"30","author":"Parsons","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1093\/annonc\/mdn692_bb0195","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1600-0420.2006.00822.x","article-title":"Ophthalmic and adnexal complications of radiotherapy","volume":"85","author":"Durkin","year":"2007","journal-title":"Acta Ophthalmol Scand."},{"key":"10.1093\/annonc\/mdn692_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archopht.1952.01700030058006","article-title":"Clinical and pathological characteristics of radiation cataract","volume":"47","author":"Cogan","year":"1952","journal-title":"Arch Ophthalmol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419407096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419407096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/4\/709\/540095\/mdn692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T12:33:31Z","timestamp":1582202011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419407096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0923753419407096"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn692","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}